Grace Koennecke - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Grace Koennecke's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Grace Koennecke
Verified
Managing Editor, ACRN (Athens, OH)
Athens
Beats
culture ruralism geography and teaching social sciences environment
Content
By Grace Koennecke| Psychiatric Times Verified MindMed recently announced that the first patient has been dosed in its phase 3 Emerge study evaluating MM120 ODT for treatment of major depressive disorder (MDD). MM120 ODT is a proprietary, pharmaceutically optimized form of lysergic acid diethylamide (LSD). MindMed will also test the efficacy and safety of MM120 ODT 100 µg compared with a placebo, with an expected enrollment of approximately 140 participants in the United States.
By Grace Koennecke| Psychiatric Times Verified Findings from a recent online research study by The Harris Poll indicated that clinicians are concerned about their patients’ quality of life as well as medications issues like adherence and switching.
By Grace Koennecke| Psychiatric Times Verified MindMed recently announced that the first patient has been dosed in its phase 3 Emerge study evaluating MM120 ODT for treatment of major depressive disorder (MDD). MM120 ODT is a proprietary, pharmaceutically optimized form of lysergic acid diethylamide (LSD). MindMed will also test the efficacy and safety of MM120 ODT 100 µg compared with a placebo, with an expected enrollment of approximately 140 participants in the United States.
Company Info
ACRN (Athens, OH)